We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I don't think LR is going anywhere soon. As for profit, well they always seem to find something to invest in to stifle profits . There is likely a massive £10/20m COVID revenue hole to fill this next year. Profit, huh! you must be joking.
Surely the only reason we will not post a full year profit is because of the investment to get the labs expanded to meet anticipated future volumes. Strip out this expense next year and, even with no further growth in revenues, we will be cash flow positive next year.
Stas20 You are pretty well on the money with your comments. RNS after RNS with nothing of any discernible value for investors to grind their teeth on. You can’t buck the market and with little or nothing for investors to grab hold of you are left with the strong impression that the company is being run for the benefit of Rees and his clan.
Until there is a change at the top and a clear out of the like minded the share price will likely remain becalmed.
Richmanpoorman, I totally agree and would wholeheartedly support getting rid of Ree's.
All this talk of what he has done for this company is just background bluster.
What I have seen is 2 years of a declining share price, huge numbers of options, even options given to acquired companies that had crap stretch targets, what was all that rubbish recently given to equity earn out milestones for what!
I have said it before and I'll continue repeating it until someone proves me wrong, the only thing Ree's has done is surround himself with sycophants and pull together deals that have no huge skill attached. Its easy to pull together partnerships that commit to little or related party transactions such as deals with MHC where you happen to be a director. Indeed I have seen nothing truly ground breaking, or stand out that shows this CEO to be anything more than a jobber.
Nothing has made this company bottom line profit generating except for some constructive EBITDA accounting. Indeed we are about to close a year with the largest revenue generation ever but at a bottom line loss?
This CEO's actions are representative of a narcissist that seems to be full of his own self importance creating a top heavy management structure that is bleeding company money but has seriously failed at delivering any shareholder value to those that support this business. Add to that the great so called city slicker chairman who has also failed to rein in the CEO demonstrates his own failure.
Sorry to say until I see a return on my investment, which considering its pretty low average should have been returned a long time ago, my vote would be to get rid of a CEO that seems to have more interrelated or cross party directorships that one man can possibly maintain, and bring one in, without the baggage, that can show the kind of attention that Yourgene obviously needs and is lacking.
Current share price = the same as in October 2019 - appalling!
I see green box has posted twice - bet he's moaning!
Well said richmsmpoorman
I only care about the bottom line.
For the company that's profit
For shareholders that's the share price!
Says it all!!
Eel
That's all noted and reads well for the future, provided that Covid revenue doesn't drop off a cliff, however every RNS which comes out about new business, contract wins, etc, has absolutely no financial details so we are totally blind as to the revenue/profit potential. It is a Chairman's job in any company to hold the BoD accountable for growing a company AND for delivering shareholder value. The former without the latter is a fool's errand. This BoD has spectacularly failed to deliver shareholder value and should therefore be held to account. They may be skilled in all matters scientific but they clearly do not have the requisite experience about how to drive forward YGEN's market cap. I'm sorry to have to say this but it's time for the Chairman to bring in a CEO with the right credentials and who is properly shareholder focused. Failure to do this is bound to result in a very obvious outcome - YGEN will be bought out for a fraction of its true value and we long-suffering shareholders will lose out. I've seen this happen too many times but it's something this BoD is sleep walking us into. Time for change.
Yes GLTrader a most welcome post, it has made me transition..from gloom to unfettered optimism . I may have been unduly influenced by the resident doomster for too long.
Well done GLTrader, A very well crafted post. There are far too many pessimistic complainers on this board who seem to massage their own egos rather than dispassionately comment on YGEN and fail to realise what has been achieved in the last 3 years or so. Many thanks.n.
YGEN has had
Top quality post GLTader
My goodness, I am getting quite disappointed with this forum. I know the share price is clouding everyone's sentiments and views, but take a moment to reflect. YGEN have just told us that they will report at least £37m revenue, with at least 10% EBITDA. By that, and given track record this financial year, I take it we will be at least meeting that, likely beating it.
Natdan - you pointed out the difference in 2021 v 2022 update. Well, firstly, there is more to explain when you miss expectations. Secondly, and more accurately, Lyn said he will update us all in January about trading performance - this following the HY results and conference all on 14 December 2021. This is specifically to address questions from the floor how busy Covid will be and size of the DHSC contracts. He said these contracts have no minimum order values so hard to tell, but he will update us as soon as he knows more. Well he just did!
Anyone who has already forgotten should refresh themselves by reading HY results, and listening to the IMC video. I just did. For your convenience, there are many growth drivers to come:
- US NIPT launch: should be live this quarter and fully from 1 April 2022. I expect this to quite quickly overtake the international NIPT sales given the quality of the partner, a leading precision medicine company launching a network of new clinical reproductive health screening across all US states. Think they only do it with minimum 80,000/annum per clinic;
- US x 2 Ranger technology clients (with more to come): Lyn said investments being made to relocate and expand Yourgene Canada to accommodate expected sales. He specifically said currently 500 cassettes (consumables) per month, ramping it up to 5,000 per month, as requested by Labcorp + ANO (to be named). More pipeline;
- Other tests: New distribution partners in ME, US and LATM, plus key hires;
- Re-applying facility for non-Covid testing and genetic sequencing: Of the tenders in, 30% are non-Covid. This is even though company expect Covid and Covid related needs to continue for the next 2 years, which I tend to agree. The DHSC contracts only serves to validate YGEN capability and will be door openers;
- Debt financing to avoid dilution for further M&A: Institutions only lend if you can provide reliable CF!
I am equally frustrated with SP performance, and I imagine so are the management! They are doing everything they feel they can and are delivering, yet not being cheered. Well, I say thank you Lyn and YGEN team for delivering us £37m revenue. Genmark Diagnostics which I referenced the other day was sold for 9x sales, and guess what, they are loss-making!
There appears to be a seller in the background since turn of year. I suspect employee/ex-employee perhaps who had options exercised at cheaper price - ppl have their reasons. Once that clears, the SP should follow the progress of the business. I have no doubt, if we crack US as expected, we will be growing further and quickly in FY22.